Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 4/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20936341 | 1.00 | KMT2A (0.49) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL6704344 | 0.92 | L3MBTL1 (0.50) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL16581621 | 0.92 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL5828119 | 0.92 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL16593160 | 0.92 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL16588593 | 0.92 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL13024817 | 0.90 | L3MBTL1 (0.43) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL18101893 | 0.90 | L3MBTL1 (0.43) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL26491385 | 0.90 | L3MBTL1 (0.43) | KMT2AMEN1L3MBTL1LGALS9LGALS1 | |
| SCHEMBL13024785 | 0.89 | L3MBTL1 (0.52) | KMT2AMEN1L3MBTL1LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102617-A1 | Specific acylation of carbohydrate hydroxyls | MOLITOR ERICH J (US) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102617-A1 | Specific acylation of carbohydrate hydroxyls | HSD17B14, FUT6, UGGT1 | KMT2A 2026/4885MEN1 3612/4885L3MBTL1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.